Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | AGXT | P21549 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12970186 | 0.82 | PKM (0.42) | APPMAOBIDO1NPC1RAB9A | |
| SCHEMBL25719809 | 0.73 | LTA4H (0.47) | IDO1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20000873 | 0.72 | APP (0.80) | APPMAOBIDO1AGXTNPC1 | |
| SCHEMBL1357421 | 0.72 | — | — | |
| SCHEMBL21872251 | 0.72 | CNR2 (0.48) | APPMAOBIDO1AGXTCNR1 | |
| SCHEMBL31553161 | 0.72 | PDE2A (0.41) | APPMAOBPDE2AIDO1AGXT | |
| SCHEMBL2629335 | 0.71 | — | — | |
| SCHEMBL22290783 | 0.71 | MAOB (0.51) | MAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL31173265 | 0.71 | MAOB (0.51) | MAOBIDO1AGXTSMN1; SMN2 | |
| SCHEMBL22306752 | 0.71 | PKM (0.41) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-109071546-B | Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors | 辉瑞大药厂 | 2021-03-02 | — | — | CN | disclosed |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2020-12-24 | — | — | US | disclosed |
| EP-3419978-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CBR1 | APP 4268/4885MAOB 2913/4885PDE2A 4401/4885 |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | APP 4351/4885MAOB 2541/4885PDE2A 4205/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | APP 4069/4885MAOB 3119/4885PDE2A 1796/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | APP 4351/4885MAOB 2541/4885PDE2A 4205/4885 |
| US-20200399281-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CBR1 | APP 4268/4885MAOB 2913/4885PDE2A 4401/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | APP 4351/4885MAOB 2541/4885PDE2A 4205/4885 |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | SYMPK, IL15, STAT6 | APP 1816/4885MAOB 4484/4885PDE2A 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.